• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Addex Therapeutics Ltd

    4/25/25 6:18:12 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email
    6-K 1 f6k_042525.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    Commission File Number: 001-39179

    Addex Therapeutics Ltd
    (Translation of registrant's name into English)

    Chemin des Mines 9,
    CH-1202 Geneva,
    Switzerland

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]


     

    On April 25, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

    Exhibits

    Exhibit Number   Description
         
    99.1   Annual Report 2024
    99.2   Press release dated April 25, 2025

    INCORPORATION BY REFERENCE

    Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

            Addex Therapeutics Ltd    
        (Registrant)
         
       
    Date: April 25, 2025       /s/ Tim Dyer    
        Tim Dyer
        Chief Executive Officer
       


    EXHIBIT INDEX 

    Exhibit Number   Description
         
    99.1   Annual Report 2024
    99.2   Press release dated April 25, 2025

    Get the next $ADXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADXN

    DatePrice TargetRatingAnalyst
    7/31/2024$30.00Neutral → Buy
    H.C. Wainwright
    2/11/2022$28.00 → $21.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADXN
    SEC Filings

    See more
    • SEC Form 6-K filed by Addex Therapeutics Ltd

      6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

      6/30/25 6:05:06 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Addex Therapeutics Ltd

      6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

      6/25/25 6:05:05 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Addex Therapeutics Ltd

      6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

      6/20/25 6:00:17 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Addex Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00

      7/31/24 6:43:32 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Addex Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $21.00 from $28.00 previously

      2/11/22 6:28:07 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Addex Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $28.00

      4/21/21 6:28:54 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Addex Shareholders Approve All Resolutions at Annual General Meeting

      Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM). The votes represented 30.18% of the company's outstanding capital. Addex shareholders approved the 2024 annual report, the 2024 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote). All motions regarding the compensation of the board of di

      6/25/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

      Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators

      6/19/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

      Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title:   Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:

      6/18/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Addex Therapeutics Ltd

      SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

      8/14/24 8:12:35 PM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Addex Therapeutics Ltd

      SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

      8/5/24 9:00:10 PM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Addex Therapeutics Ltd (Amendment)

      SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

      12/8/23 2:11:53 PM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

      Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. "It's great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex

      8/2/21 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADXN
    Financials

    Live finance-specific insights

    See more
    • Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

      Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators

      6/19/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

      Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title:   Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:

      6/18/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

      Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators

      4/25/25 1:00:00 AM ET
      $ADXN
      Biotechnology: Pharmaceutical Preparations
      Health Care